Pearl Street Venture Funds
Pearl Street Venture Funds is a venture capital firm founded in 2003 and headquartered in Indianapolis, Indiana. The firm specializes in early-stage investments, particularly in the life sciences sector, focusing on biotechnology, pharmaceuticals, medical devices, and agri-bio. It actively seeks opportunities in therapeutic product companies that are developing advanced technologies. Pearl Street Venture Funds has a specific interest in supporting companies based in Indiana and is capable of acting as both a lead and co-investor. While it is currently fully invested and not making new investments, its commitment to delivering superior financial returns for its limited partners remains a core objective. The firm also maintains additional offices in Los Angeles, West Lafayette, San Diego, and Gaithersburg.
Toggle is a company based in the United States that specializes in robotics as a service (RaaS) for the construction industry, specifically focusing on the assembly of rebar cages for reinforced concrete. The company has developed two-arm robotic platforms and proprietary jig designs that enable the construction of rebar structures directly from computer blueprints, allowing for greater precision and efficiency in construction processes. By integrating industrial robotics and automation into traditional construction methods, Toggle aims to transform the way infrastructure and buildings are created, addressing the increasing complexity of modern construction projects.
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.
Serenex is a medical drug discovery and development company that focuses on oncology. The company develops Hsp90 product platform that provides a collection of small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases, such as Alzheimer's. It also develops SNX-1012, a product for oral mucositis in solid tumor patients. Serenex is a U.S.-based company that was founded in 2000 and it was acquired in 2008 by Pfizer.
BioVigilant Systems invented instantaneous microbial detection technology to address environmental monitoring needs in pharmaceutical, biotechnology, healthcare, and environmental applications. BioVigilant’s IMD systems detect—instantaneously and in real time—particulate count, size, and biological status. Unlike other rapid microbial methods, BioVigilant’s optically-based systems require no staining, no reagents, no waiting period, and little human intervention.
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.